Castle Biosciences (CSTL) CFO reports RSU grant, option exercise and share sales
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Castle Biosciences Chief Financial Officer Frank Stokes reported a mix of stock awards, option exercises, sales, and tax-related share withholdings. On March 3, 2026, he was granted 48,367 Restricted Stock Units (RSUs), each representing one share of common stock, vesting in four equal annual installments beginning March 3, 2027.
That same day, he sold 5,300 and 1,700 shares of common stock at weighted-average prices of $27.32 and $27.81 in open-market transactions under a Rule 10b5‑1 trading plan. He also disposed of 3,611 shares at $27.57 to cover tax withholding on previously vested performance stock units.
On March 4, 2026, Stokes exercised derivative awards, converting 12,186 and 11,960 RSUs and 3,800 fully vested stock options into common stock, including 3,800 shares at an exercise price of $3.38. After these transactions, he directly owned 66,086 common shares, including 1,033 shares acquired under the employee stock purchase plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 7,000 shares ($192,073)
Net Sell
10 txns
Insider
Stokes Frank
Role
Chief Financial Officer
Sold
7,000 shs ($192K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 12,186 | $0.00 | -- |
| Exercise | Restricted Stock Units | 11,960 | $0.00 | -- |
| Exercise | Stock option (right to buy) | 3,800 | $0.00 | -- |
| Exercise | Common Stock | 24,146 | $0.00 | -- |
| Tax Withholding | Common Stock | 10,732 | $28.17 | $302K |
| Exercise | Common Stock | 3,800 | $3.38 | $13K |
| Grant/Award | Restricted Stock Units | 48,367 | $0.00 | -- |
| Sale | Common Stock | 5,300 | $27.32 | $145K |
| Sale | Common Stock | 1,700 | $27.81 | $47K |
| Tax Withholding | Common Stock | 3,611 | $27.57 | $100K |
Holdings After Transaction:
Restricted Stock Units — 24,372 shares (Direct);
Stock option (right to buy) — 14,912 shares (Direct);
Common Stock — 73,018 shares (Direct)
Footnotes (1)
- The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Frank Stokes on November 13, 2025. This transaction was executed in multiple trades at prices ranging from $26.70 to $27.67, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Includes 1,033 shares acquired on February 27, 2026, under the Issuer's employee stock purchase plan. This transaction was executed in multiple trades at prices ranging from $27.72 to $27.97, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Reflects the withholding of shares of the Issuer's common stock to satisfy tax withholding obligations in connection with the delivery of vested performance stock units reported on January 12, 2026. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. The RSU's vest in four equal annual installments beginning on March 03, 2027. On March 4, 2024, the Reporting Person was granted 48,744 RSUs which vest in four equal installments beginning on March 4, 2025. On March 4, 2025, the Reporting Person was granted 47,838 RSUs which vest in four equal installments beginning on March 4, 2026. The shares subject to the option are fully vested.
FAQ
What insider transactions did CSTL CFO Frank Stokes report on this Form 4?
Frank Stokes reported a mix of equity award activity, option exercises, open-market sales, and tax-related share withholdings. The filing details RSU grants, conversions of RSUs and options into common stock, sales executed under a Rule 10b5-1 plan, and shares withheld to satisfy tax obligations.
What RSU grant did CSTL CFO Frank Stokes receive on March 3, 2026?
On March 3, 2026, the CFO received 48,367 Restricted Stock Units (RSUs). Each RSU represents the right to receive one share of Castle Biosciences common stock, and these RSUs vest in four equal annual installments beginning on March 3, 2027, according to the filing footnotes.
What is the significance of the Rule 10b5-1 plan mentioned in the CSTL Form 4?
The Form 4 states that the reported transaction was made under a Rule 10b5-1 trading plan adopted on November 13, 2025. Such plans pre-schedule trades, allowing insiders to sell shares according to predetermined instructions, helping separate trading activity from day-to-day discretionary decisions.